An interventional study of Hyper-personalized feedback (HPF intervention) and Targeted auditory stimulation during sleep (TASS verum intervention) in Parkinson Disease, sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by University of Zurich · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Parkinson Disease with a site in Switzerland — 31 open to participants now, 34 under way, none of them phase 3. Parkinson Disease · Switzerland.
Among the 85 studies in Parkinson Disease with a site in Switzerland, this one is the 25th largest by planned enrollment of the 67 interventional ones that give a count, is one of 9 that started in 2024, is one of 49 with no phase, reaches primary completion later than 12 of the 33 other live ones, and was the 68th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →31 of the 85 studies in Parkinson Disease with a site in Switzerland are open now. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–75
Siegward -M. Elsas · Sites in Switzerland
Ages 50–79
University of Zurich · Sites in Switzerland
Ages 18+
University of Zurich · Sites in Switzerland
Alain Kaelin · Sites in Switzerland
Ages 50–80
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 4 · Phase 4 3
First in 2002; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 30 across the 67 interventional studies, 64 across the 18 observational. Of the 45 that completed or were terminated, 6 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 85 have an industry lead sponsor. The 10 most frequent:
University of Zurich is the lead sponsor of 1,051 studies on the registry; 134 are open to participants now.
University of Zurich has 8 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
12 of the studies in Parkinson Disease with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06831500Julien BallyFeasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. | 2026-11 |
| NCT07485218University of Applied Sciences and Arts of Southern SwitzerlandMultidimensional Assessment of Fatigability in Older Adults Living in Southern Switzerland and Elderly With Parkinson's Disease | 2026-12 |
| NCT06608875University of ZurichPrecision Sensorimotor Neurorehabilitation Through Personalized Stimulation Loops | 2026-12 |
| NCT05765110Insel Gruppe AG, University Hospital BernSPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease | 2026-12-31 |
| NCT07802509Klinik ValensDoes Hippotherapy Have an Effect on Mobility, Gait, Balance and Perceived Health-related Quality of Life in Persons With Parkinson's Disease? | 2027-01-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 85 studies in Parkinson Disease with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Parkinson's disease (PD) is a neurodegenerative disease that affects about 1% of the elderly population and accounts for substantial disability and health care costs.
Disability is largely driven by mobility deficits caused by impaired gait. Effective treatments are available to restore lower limb function and improve gait, but response to treatment varies greatly from patient to patient and often shows only small effect sizes. Addressing this heterogeneity requires personalization, a concept referred to precision neurorehabilitation.
StimuLOOP.PD intends to foster structured and reproducible methods for precision neurorehabilitation of gait in PD. The investigator will conduct a proof-of-concept study to investigate a combination of two methods that are each tailored to the individual patient. Two innovative technologies are applied in concert to enhance recovery of lower limb function.
The HPF intervention is expected to induce rapid adaptations, which however do not persist over multiple days. To counter this, the investigator will leverage memory reactivation during sleep to enhance the consolidation of the movement patterns that are learned during HPF.
The investigator expect that these interventions will lead to greater gains in functional walking ability. Beyond demonstrating a proof-of-concept for novel methods of precision neurorehabilitation, positive results of this project may have implications for neurorehabilitation treatment in general by providing first insights into the benefits and interplay of HPF and TASS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hyper-personalized feedback-based motor rehabilitation with sham targeted auditory stimulation during sleep (HPF intervention, TASS sham intervention)
Behavioral: Hyper-personalized feedback (HPF intervention) · Behavioral: Control targeted auditory stimulation during sleep (TASS sham intervention)
Hyper-personalized feedback-based motor rehabilitation with targeted auditory stimulation during sleep (HPF intervention, TASS verum intervention)
Behavioral: Hyper-personalized feedback (HPF intervention) · Behavioral: Targeted auditory stimulation during sleep (TASS verum intervention)
For lower limb motor rehabilitation, the investigator will employ real-time continuous feedback for movement aspects that are specific to each participant's motor deficit. The feedback will be adapted and tailored to each participant.
The investigator aim to reactivate rehabilitation- related memories through the presentation of auditory stimuli during sleep with the goal of promoting motor memory consolidation into stable motor commands
Identical auditory presentation during the motor rehabilitation training, but not during the night (sham promotion memory reactivation)
6 min walking test
Change in functional walking ability assessed with the 6 min walking test
Time frame: Pre, immediately post motor rehabilitation and 1 month post motor rehabilitation
MiniBEST test
the change in postural stability assessed with the MiniBEST test
Time frame: Pre, immediately post motor rehabilitation and 1 month post motor rehabilitation
Phase Coordination Index
Motor learning assessed via changes in coordination. Coordination assessed using the Phase Coordination Index.
Time frame: Pre, immediately post motor rehabilitation training and during 15 days of motor rehabilitation training and one-month post-training
Continuous Relative Phase
Motor learning assessed via changes in coordination. Coordination assessed using Continous Relative Phase.
Time frame: Pre, immediately post motor rehabilitation training and during 15 days of motor rehabilitation training and one-month post-training
Variability
Motor learning assessed via changes in variability. Variability assessed using the coefficient of variation (%CV) of common spatio-temporal gait parameters, including stride time, stride length, step length, swing time, stance time, step width, and double limb support time.
Time frame: Pre, immediately post motor rehabilitation training and during 15 days of motor rehabilitation training and one-month post-training
Symmetry
Motor learning assessed via changes in symmetry. Symmetry (%) in step length and step time.
Time frame: Pre, immediately post motor rehabilitation training and during 15 days of motor rehabilitation training and one-month post-training
Margin of Stability
Motor learning assessed via changes in stability. Stability assessed using Margin of Stability.
Time frame: Pre, immediately post motor rehabilitation training and during 15 days of motor rehabilitation training and one-month post-training
Resilience
Motor learning assessed via changes in stability: Stability assessed using resilience metrics.
Time frame: Pre, immediately post motor rehabilitation training and during 15 days of motor rehabilitation training and one-month post-training
Standard sleep architecture measures
Single-channel sleep Electroencephalography (EEG): (e.g. % N3, % N2, wake after sleep onset, Sleep efficiency) from scored EEG, electromyography (EMG), and electrooculography (EOG) signal (note: bandpass filtered EMG and EOG signal will only be used for offline sleep scoring according to American Academy of Sleep Medicine standards)
Time frame: During 15 days of motor rehabilitation training
Event related spectral perturbation (ERSP)
ERSP: \[µV\^2/Hz or % or dB of baseline if normalized over time\] and event-related potential (ERP) \[µV over time\] locked to stimuli from frontal, single-channel EEG signal
Time frame: During 15 days of motor rehabilitation training
Frequency spectrum
Single-channel sleep EEG: \[µV\^2/Hz\] from frontal, single-channel EEG signal
Time frame: During 15 days of motor rehabilitation training
Slow-wave activity
Single-channel sleep EEG: \[µV\^2/Hz or % or dB of baseline if normalized\] in scored non-rapid eye movement (NREM) sleep from frontal, single-channel EEG signal
Time frame: During 15 days of motor rehabilitation training
Sigma power
Single-channel sleep EEG: \[µV\^2/Hz or % or dB of baseline if normalized\] in scored NREM sleep from frontal, single-channel EEG signal
Time frame: During 15 days of motor rehabilitation training
Quantity
Single-channel sleep EEG: density \[number/min\], and characteristics (amplitude, peak frequency, bandwidth) of sleep oscillations (spindles, K-complexes, slow-wave-spindle-coupling) in scored NREM sleep from frontal, single-channel EEG signal.
Time frame: During 15 days of motor rehabilitation training
Quality of Life (EQ-5D-5L)
Patient-Reported Outcomes (PRO) measurement that can assess patients' quality of life, irrespective of the disease. Quality of life scale developed by EuroQol Group called EQ-5D-5L, scoring from level 1 indicating no problem to level 5 indicating extreme problems.
Time frame: Pre motor rehabilitation training and 1 month after training
Plan to share: No
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 31 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.